AR042486A1 - Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . - Google Patents

Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .

Info

Publication number
AR042486A1
AR042486A1 ARP030104653A ARP030104653A AR042486A1 AR 042486 A1 AR042486 A1 AR 042486A1 AR P030104653 A ARP030104653 A AR P030104653A AR P030104653 A ARP030104653 A AR P030104653A AR 042486 A1 AR042486 A1 AR 042486A1
Authority
AR
Argentina
Prior art keywords
alkyl
aromatic ring
hydroxy
aromatic
optionally substituted
Prior art date
Application number
ARP030104653A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR042486A1 publication Critical patent/AR042486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Compuesto de quinolina y nafteridina halosustituido en la posición 3 que tiene la fórmula (1) en la cual Z1 es N o CR1a, R1 y R1a se seleccionan independientemente entre H, nitro, halógeno, alquiltio (C1-3), alquilo (C1-3) y alcoxi (C1-3) opcionalmente sustituidos con alcoxi (C1-3); o R1 y R1a están conjuntamente unidos para formar un grupo etilendioxi, R1b es H o halógeno; con la condición de que cuando Z1 es N entonces R1b es H y cuando Z1 es CR1a entonces R1 no es H; R1c es halógeno; AB es -CHR6-CO o CHR6-CH2; R6 es H, NH2, CH2OH o hidroxi; R3 es hasta dos sustituyentes seleccionados entre H, halógeno, alquilo (C1-3), hidroxi-alquilo (C1-3), -CONH2, -COOH, -CH2CONH2, -CH2COOH, -CONCH3 e hidroxi en la porción 3 opcionalmente sustituidos con alquilo (C1-3); R4 es un grupo -U-R5 en donde R5 es un sistema (A) de anillos carbocíclicos o heterocíclicos, bicíclico, sustituido o sin sustituir (como se muestra en la fórmula (2), que contiene hasta cuatro heteroátomos en cada anillo y en el cual al menos uno de los anillos (a) y (b) es aromático; X1 es C o N cuando es parte de un anillo aromático o CR14 cuando es parte de un anillo no aromático; X2 es N, NR13, O, S(O)x, CO o CR14 cuando es parte de un anillo aromático o no aromático o puede ser además CR14R15 cuando es parte de un anillo no aromático; X3 y X5 son independientemente N o C; Y1 es un grupo conector de 0 a 4 átomos, en el que cada átomo se selecciona independientemente entre N, NR13, O, S(O)x, CO y CR14 cuando es parte de un anillo aromático o no aromático o puede ser adicionalmente CR14R15 cuando es parte de un anillo no aromático; Y2 es un grupo conector de 2 a 6 átomos, en el que cada átomo de Y2 se selecciona independientemente entre N, NR13, O, S(O)x, CO y CR14 cuando es parte de un anillo aromático o no aromático o puede ser adicionalmente CR14R15 cuando es parte de un anillo no aromático; cada uno de R14 y R15 se selecciona independientemente entre H, alquiltio (C1-4), halo, alquilo (C1-4), alquenilo (C2-4), hidroxi, hidroxi-alquilo (C1-4), mercapto-alquilo (C1-4), alcoxi (C1-4), trifluorometoxi, nitro, ciano, carboxi, amino o aminocarbonilo opcionalmente sustituido con alquilo (C1-4); cada R13 es independientemente H, trifluorometilo, alquilo (C1-4) opcionalmente sustituido con hidroxi, carboxi, alcoxi (C1-4), alquiltio (C1-6), halo o trifluorometilo; alquenilo (C2-4), o aminocarbonilo en el que el grupo amino está opcionalmente sustituido con alquilo (C1-4); cada x es independientemente 0, 1 o 2, y U es CO, SO2 o CH2; o una sal farmacéuticamente aceptable del mismo. Se provee también un procedimiento para preparar un compuesto de la fórmula (1). Composición farmacéutica que comprende el compuesto y un vehículo farmacéuticamente aceptable, y su uso para preparar una composición farmacéutica para tratar infecciones bacterianas en mamíferos, particularmente seres humanos.
ARP030104653A 2002-12-18 2003-12-16 Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . AR042486A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43472902P 2002-12-18 2002-12-18
US45701303P 2003-03-24 2003-03-24

Publications (1)

Publication Number Publication Date
AR042486A1 true AR042486A1 (es) 2005-06-22

Family

ID=32685334

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104653A AR042486A1 (es) 2002-12-18 2003-12-16 Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .

Country Status (7)

Country Link
US (1) US20060041123A1 (es)
EP (1) EP1578743A4 (es)
JP (1) JP2006511622A (es)
AR (1) AR042486A1 (es)
AU (1) AU2003300965A1 (es)
TW (1) TW200427688A (es)
WO (1) WO2004058144A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
AU2003294565A1 (en) 2002-12-04 2004-06-23 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
US7691850B2 (en) * 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
WO2006014580A1 (en) * 2004-07-08 2006-02-09 Glaxo Group Limited Antibacterial agents
US20080194547A1 (en) * 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
WO2006020561A2 (en) * 2004-08-09 2006-02-23 Glaxo Group Limited Antibacterial agents
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP2008528587A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
NZ562034A (en) 2005-03-31 2009-10-30 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as antibacterial agents
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EA200801128A1 (ru) 2005-10-21 2008-10-30 Глэксо Груп Лимитед Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
ES2376488T3 (es) 2006-01-26 2012-03-14 Actelion Pharmaceuticals Ltd. Antibióticos de tetrahidropirano.
WO2007093963A1 (en) 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
AU2007224020A1 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
TW200804336A (en) * 2006-03-23 2008-01-16 Actelion Pharmaceuticals Ltd Cyclohexyl or piperidinyl carboxamide antibiotic derivatives
JP2009532504A (ja) * 2006-04-06 2009-09-10 グラクソ グループ リミテッド 抗菌薬
US7709483B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
GB0608263D0 (en) * 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
KR20090087867A (ko) * 2006-08-30 2009-08-18 리서치 파운데이션 오브 더 시티 유니버시티 오브 뉴욕 항균성 조성물
DK2074123T3 (da) * 2006-10-16 2013-01-14 Bionomics Ltd Nye anxiolytiske forbindelser
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
CL2007003693A1 (es) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CL2008001003A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
DE602008002912D1 (de) * 2007-04-20 2010-11-18 Glaxo Group Ltd Tricyclische stickstoffhaltige verbindungen als antibakterielle wirkstoffe
US9832998B2 (en) 2007-05-30 2017-12-05 Research Foundation Of The City University Of New York Antiviral compositions
US8470351B2 (en) * 2007-05-30 2013-06-25 The Research Foundation Of The City University Of New York Embedding antibiotic compounds in solid polymers
WO2009041999A1 (en) * 2007-05-30 2009-04-02 Research Foundation Of The City University Of New York Antiviral compositions
AU2008330725B2 (en) * 2007-11-26 2013-05-30 Taisho Pharmaceutical Co., Ltd. Novel naphthyridine derivative monohydrate and method for producing the same
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
WO2009128019A1 (en) 2008-04-15 2009-10-22 Actelion Pharmaceuticals Ltd Tricyclic antibiotics
AU2009278791A1 (en) 2008-08-04 2010-02-11 Actelion Pharmaceuticals Ltd Tricyclic alkylaminomethyloxazolidinone derivatives
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
DK2344495T3 (en) 2008-10-07 2015-02-02 Actelion Pharmaceuticals Ltd TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
EP2352734A1 (en) 2008-10-17 2011-08-10 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
CN102232078B (zh) 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
US8318940B2 (en) 2009-01-15 2012-11-27 Glaxo Group Limited Naphthyridin-2 (1 H)-one compounds useful as antibacterials
CA2750047A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN102666548B (zh) 2009-12-18 2015-07-15 巴斯利尔药物股份公司 三环抗生素
ES2574179T3 (es) * 2010-07-20 2016-06-15 Glaxo Group Limited Procedimiento para preparar derivados de pirano-[2,3-c]piridina
AU2012222874B2 (en) 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
WO2012171860A1 (en) 2011-06-17 2012-12-20 Basilea Pharmaceutica Ag Tricyclic antibiotics
WO2013080156A1 (en) 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
CN102491985B (zh) * 2011-12-13 2014-04-09 南京药石药物研发有限公司 6-氨基-2，2-二甲基-2H-吡啶[3，2-b][1，4]恶嗪-3(4H)-酮的合成方法
AR089929A1 (es) * 2012-02-10 2014-10-01 Actelion Pharmaceuticals Ltd Proceso para manufacturar un derivado de naftiridina
AR090844A1 (es) * 2012-04-27 2014-12-10 Actelion Pharmaceuticals Ltd Proceso para elaborar derivados de naftiridina
CN102838548B (zh) * 2012-09-12 2014-12-17 济南纽华医药科技有限公司 用作医药和农药中间体的3-氯-5-氨基哒嗪的合成方法
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
CR20170069A (es) 2014-08-22 2017-04-28 Glaxosmithkline Intelectual Property Dev Ltd Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
JP6878316B2 (ja) * 2015-06-19 2021-05-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
UY36851A (es) 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
EP3927703B1 (en) 2019-02-19 2023-04-05 Univerza V Ljubljani Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228098B1 (en) * 1998-07-10 2001-05-08 General Surgical Innovations, Inc. Apparatus and method for surgical fastening
GB9822440D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9917406D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US6403610B1 (en) * 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
US6803369B1 (en) * 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
CZ2003243A3 (cs) * 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
US6603005B2 (en) * 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6602884B2 (en) * 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030203917A1 (en) * 2001-07-25 2003-10-30 Smithkline Beecham Corporation And Smithkline Beecham P.L.C. Compounds and methods for the treatment of neoplastic disease
GB0118238D0 (en) * 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003064431A2 (en) * 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
JP4445753B2 (ja) * 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) * 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) * 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
AU2003301414B8 (en) * 2002-10-10 2010-06-17 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel compounds with antibacterial activity
AU2003291227A1 (en) * 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
US7232832B2 (en) * 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
AU2003294565A1 (en) * 2002-12-04 2004-06-23 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
US7232833B2 (en) * 2003-03-28 2007-06-19 Novexel 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7348434B2 (en) * 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2006511622A (ja) 2006-04-06
WO2004058144A2 (en) 2004-07-15
EP1578743A4 (en) 2006-11-29
US20060041123A1 (en) 2006-02-23
WO2004058144A3 (en) 2004-10-21
AU2003300965A1 (en) 2004-07-22
TW200427688A (en) 2004-12-16
AU2003300965A8 (en) 2004-07-22
EP1578743A2 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
AR042486A1 (es) Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
AR043938A1 (es) Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
EA200401579A1 (ru) Замещенные соединения метациклина (варианты), фармацевтическая композиция (варианты) и способ лечения чувствительного к тетрациклину состояния млекопитающего (варианты)
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
AR034669A1 (es) Derivados de tetrahidroquinolina y su uso para controlar la fertilidad
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
DK0995743T3 (da) Dihydro- og tetrahydroquinolinderivater, som medicinsk antioxidant
BR0008753B1 (pt) Composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
BRPI0414450A (pt) derivados de diazabicicloalcano substituìdos como ligandos nos receptores de alfa 7 acetilcolina nicotìnica
AR054214A1 (es) Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c.
HRP20100194T8 (en) Peri condensed tricyclic compounds useful as antibacterial agents
EA200400991A1 (ru) Фармацевтические композиции, содержащие ингибиторы протеазы вируса гепатита c
AR038863A1 (es) Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero
UY27503A1 (es) Nuevos derivados de piperazina
BR9711095A (pt) Composto de ciclopentano substituìdo, composição e método para inibir neuraminidase de vìrus influenza e método para tratar infecção de vìrus influenza
WO2007022502A3 (en) Bridged n-cyclic sulfonamido inhibitors of gamma secretase
EA200401526A1 (ru) Новые соединения и их применение
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
ATE359786T1 (de) Camptothecin derivate
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
AR045793A1 (es) Compuestos derivados de 3-heterociclil-indol
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
MXPA04006041A (es) Antivirales de piridoquinoxalina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal